The putative interaction of the SOS1 inhibitor BAY-293 (Merck, Darmstadt, Germany) and the BET PROTAC ARV-771 (Arvinas, New Haven, CT, USA) has been checked using BH1467 (KRAS G12C NSCLC) and EGI-1 (KRAS G12A, cholangiocarcinoma cell line) in pilot experiments at our institution. Here, KRAS is linked to cholangiocarcinoma.